Olema Pharmaceuticals, Inc. OLMA

OLMA Company Overview

Olema Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, particularly estrogen receptor (ER)-positive breast cancer. The company operates within the biotechnology and oncology sectors and concentrates on endocrine-driven cancers where resistance to standard hormonal therapies remains a significant clinical challenge. Olema’s primary value driver is its pipeline of selective estrogen receptor antagonists and related precision oncology programs designed to improve outcomes for patients with hormone receptor-positive malignancies.

The company’s lead product candidate is palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader (SERD) being evaluated in advanced and metastatic breast cancer settings. Olema was founded in 2006 and later became publicly traded on Nasdaq under the ticker OLMA following its initial public offering in 2020. Since its founding, the company has evolved from a discovery-stage oncology platform into a clinical-stage developer with an emphasis on combination therapies, biomarker-driven treatment approaches, and next-generation endocrine therapies intended to address resistance mechanisms associated with current standards of care.